Egypt: Rameda reports profit growth in 2022

The company generated consolidated revenue of $48mln in the full-year ended December 31st 2022

Staff Writer, Arab Finance

March 7, 2023

PHOTO

Egypt - Tenth of Ramadan for Pharmaceuticals Industries and Diagnostic Reagents (Rameda) (RMDA) posted a consolidated net profit attributable to the parent company of EGP 245.676 million in 2022, compared to EGP 181.088 million in 2021, according to the company’s financial statements filed to the Egyptian Exchange (EGX) on March 7th.

The company generated consolidated revenue of EGP 1.483 billion in the full-year ended December 31st 2022, jumping from EGP 1.246 billion in 2021.

Meanwhile, Rameda’s standalone net profit after tax rose to EGP 234.644 million last year from EGP 182.205 million in 2021.

Rameda is an Egypt-based pharmaceutical company that manufactures both human and veterinary pharmaceuticals.

Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.

ZAWYA NEWSLETTERS

RELATED ARTICLES

ZAWYA NEWSLETTERS

LATEST VIDEO